MBK Partners to acquire Japan pharma for KRW 3 trillion
By Kim, Jin-Gu | translator Kang, Shin-Kook
24.07.04 05:00:00
가나다라
0
Has decided to acuire Japan’s Alinamin Pharmaceutical
The company acquired Medit, Osstem Implant, Geo-Young, and set to acquire Alinamin Pharmaceutical…has completed blockbuster M&As of 'over KRW 2 trillion'
MBK Partners has been actively pursuing M&A in the biopharmaceutical and healthcare sectors in South Korea and overseas. Within the past year and a half, the company acquired Medit, Osstem Implant, and Geo-Young. The value of these M&As amounted to KRW 11 trillion.
According to foreign press on July 3rd, MBK Partners agreed to acquire Japanese company Alinamin Pharmaceutical from Blackstone for JPY 350 billion on the same day.
Alinamin Pharmaceutical was previously a business unit of Takeda Pharmaceutical. In
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)